VALNEVA (EPA:VLA) | WebDisclosure

PRESS RELEASE

published on 04/26/2025 at 19:10, 10 months 29 days ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Valneva SE provides an update on the recommendation for the use of its Chikungunya vaccine by French authorities, focusing on adverse events in elderly people. The company is collaborating with regulators on next steps

Valneva SE Chikungunya Vaccine French Authorities Adverse Events Elderly
BRIEF

published on 04/18/2025 at 10:05, 11 months 7 days ago

Valneva Updates on Chikungunya Vaccine Recommendation in the U.S.

Valneva Chikungunya Vaccine IXCHIQ® ACIP Recommendation U.S. Travelers
BRIEF

published on 04/18/2025 at 10:05, 11 months 7 days ago

Valneva met à jour sa recommandation concernant le vaccin contre le chikungunya aux États-Unis

Valneva Voyageurs Américains Vaccin Contre Le Chikungunya IXCHIQ® Recommandation De L'ACIP
PRESS RELEASE

published on 04/18/2025 at 10:00, 11 months 7 days ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva provides update on ACIP recommendation for its chikungunya vaccine IXCHIQ® among U.S. travelers, highlighting new precaution for persons aged 65 years and ongoing safety monitoring

Valneva CDC Chikungunya Vaccine IXCHIQ® ACIP Recommendation
PRESS RELEASE

published on 04/18/2025 at 10:00, 11 months 7 days ago

Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya

Valneva Vaccin Chikungunya IXCHIQ® ACIP
BRIEF

published on 04/09/2025 at 07:05, 11 months 16 days ago

Vaccination du premier enfant dans l'étude de Phase 2 sur le vaccin S4V2 contre la shigellose

Valneva Phase 2 Shigellose Vaccin S4V2 Essai Pédiatrique
BRIEF

published on 04/09/2025 at 07:05, 11 months 16 days ago

First child vaccinated in Phase 2 study of S4V2 shigellosis vaccine

Valneva Phase 2 Shigellosis S4V2 Vaccine Pediatric Trial
PRESS RELEASE

published on 04/09/2025 at 07:00, 11 months 16 days ago

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Valneva Vaccin Shigellose LimmaTech Étude Pédiatrique
PRESS RELEASE

published on 04/09/2025 at 07:00, 11 months 16 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease

Valneva Phase 2 Study Shigella Vaccine Shigellosis LimmaTech
PRESS RELEASE

published on 03/20/2025 at 07:00, 1 year ago

Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières

Published on 03/25/2026 at 19:15, 2 hours 43 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 8 hours 28 minutes ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 8 hours 28 minutes ago

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Published on 03/25/2026 at 13:30, 8 hours 28 minutes ago

Strategic Metals Closes Project Sale
Published on 03/25/2026 at 13:25, 8 hours 33 minutes ago

Predictiv AI Expands Active Deployment of CloudRep.ai Across Healthcare, Retail, Real Estate, Travel and Global Markets

View all ACCESSWIRE

Published on 03/25/2026 at 20:00, 1 hour 58 minutes ago

Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 2 hours 17 minutes ago

EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 2 hours 28 minutes ago

AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 2 hours 32 minutes ago

EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 18:40, 3 hours 18 minutes ago

TULKUBASH AND KYZYLTASH MINING ASSETS: DECLARATION FROM A GROUP OF INVESTORS

View all EQS

Published on 03/25/2026 at 18:53, 3 hours 4 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Published on 03/25/2026 at 18:53, 3 hours 5 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 3 hours 27 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 18:31, 3 hours 27 minutes ago

Performance soutenue des Investissements et déploiement actif de la stratégie
Published on 03/25/2026 at 18:06, 3 hours 52 minutes ago

LNA SANTE : Résultats Annuels 2025

View all LES ECHOS COMFI WIRE

News